Patienterne kan fortsætte behandlingen med Herceptin i perioder med reversibel, kemoterapi- induceret suppression af knoglemarven, men de skal monitoreres omhyggeligt for komplikationer relateret til neutropeni i denne periode.
Patients may continue Herceptin therapy during periods of reversible, chemotherapy-induced myelosuppression but they should be monitored carefully for complications of neutropenia during this time.